null Option on DexCom Inc

DXCM Stock  USD 82.93  0.65  0.78%   
DexCom's latest option contracts expiring on September 19th 2025 are carrying combined implied volatility of 0.57 with a put-to-call open interest ratio of 1.05 over 43 outstanding agreements suggesting investors are buying slightly more puts than calls on contracts expiring on September 19th 2025. The total put volume is at 141, with calls trading at the volume of 7.0. This yields a 20.14 put-to-call volume ratio.

Open Interest Against September 19th 2025 Option Contracts

The chart above shows DexCom's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. DexCom's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for DexCom's option, there is no secondary market available for investors to trade.

DexCom Maximum Pain Price Across 2025-09-19 Option Contracts

Max pain occurs when DexCom's market makers reach a net positive position across all DexCom's options at a strike price where option holders stand to lose the most money. By contrast, DexCom's option sellers may reap the most after selling more options than buying, causing them to expire worthless.

In The Money vs. Out of Money Option Contracts on DexCom

Analyzing DexCom's in-the-money options over time can help investors to take a profitable long position in DexCom regardless of its overall volatility. This is especially true when DexCom's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money DexCom's options could be used as guardians of the underlying stock as they move almost dollar for dollar with DexCom's stock while costing only a fraction of its price.
Please note that buying 'in-the-money' options on DexCom lessens the impact of time decay, as they carry both intrinsic and time value. So, even if DexCom's value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money DexCom contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if DexCom Stock moves the wrong way.

DexCom Inc In The Money Call Balance

When DexCom's strike price is surpassing the current stock price, the option contract against DexCom Inc stock is said to be in the money. When it comes to buying DexCom's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on DexCom Inc are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

DexCom Current Options Market Mood

DexCom's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps DexCom Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Unfortunately, most DexCom's options investors are not very successful. DexCom's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current DexCom contract

Base on the Rule 16, the options market is currently suggesting that DexCom Inc will have an average daily up or down price movement of about 0.0356% per day over the life of the 2025-09-19 option contract. With DexCom trading at USD 82.93, that is roughly USD 0.0295. If you think that the market is fully incorporating DexCom's daily price movement you should consider buying DexCom Inc options at the current volatility level of 0.57%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing DexCom options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" DexCom calls. Remember, the seller must deliver DexCom Inc stock to the call owner when a call is exercised.

DexCom Option Chain

When DexCom's strike price is surpassing the current stock price, the option contract against DexCom Inc stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
DexCom's option chain is a display of a range of information that helps investors for ways to trade options on DexCom. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for DexCom. It also shows strike prices and maturity days for a DexCom against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
DXCM250919C001350001135.00.0 - 0.50.5Out
Call
DXCM250919C00130000189130.00.0 - 0.350.5Out
Call
DXCM250919C0012500099125.00.0 - 0.850.45Out
Call
DXCM250919C00120000151120.00.15 - 0.30.25Out
Call
DXCM250919C00115000396115.00.25 - 0.50.45Out
Call
DXCM250919C00110000730110.00.5 - 0.60.74Out
Call
DXCM250919C001050001278105.00.8 - 1.01.05Out
Call
DXCM250919C00100000586100.01.4 - 1.61.8Out
Call
DXCM250919C00095000133395.02.3 - 2.52.95Out
Call
DXCM250919C00090000163990.03.7 - 3.93.85Out
Call
DXCM250919C00085000215285.05.6 - 5.95.86Out
Call
DXCM250919C00080000115880.08.2 - 8.58.8In
Call
DXCM250919C00075000197975.011.4 - 11.912.1In
Call
DXCM250919C0007000036570.015.1 - 15.719.1In
Call
DXCM250919C000650008765.019.4 - 19.919.5In
Call
DXCM250919C000600005360.023.8 - 24.425.85In
Call
DXCM250919C00055000555.027.9 - 29.630.5In
Call
DXCM250919C000500001050.032.0 - 34.232.0In
Call
DXCM250919C00045000645.038.0 - 38.940.88In
Call
DXCM250919C00040000440.042.9 - 43.942.9In
Call
DXCM250919C00035000135.047.4 - 48.947.4In
 Put
DXCM250919P001350000135.051.3 - 53.351.3In
 Put
DXCM250919P001300000130.046.3 - 47.946.3In
 Put
DXCM250919P001250000125.041.6 - 42.741.6In
 Put
DXCM250919P001200000120.036.0 - 37.636.0In
 Put
DXCM250919P001150000115.031.5 - 32.828.95In
 Put
DXCM250919P001100000110.026.7 - 27.826.7In
 Put
DXCM250919P001050000105.022.2 - 22.922.2In
 Put
DXCM250919P0010000070100.017.7 - 18.318.3In
 Put
DXCM250919P0009500028695.013.6 - 14.010.9In
 Put
DXCM250919P0009000072690.010.0 - 10.39.4In
 Put
DXCM250919P0008500095185.07.0 - 7.37.3In
 Put
DXCM250919P00080000389780.04.6 - 4.94.72Out
 Put
DXCM250919P00075000132375.02.85 - 3.02.95Out
 Put
DXCM250919P0007000096570.01.65 - 1.751.75Out
 Put
DXCM250919P00065000104465.00.95 - 1.10.95Out
 Put
DXCM250919P0006000047960.00.5 - 0.650.6Out
 Put
DXCM250919P00055000115555.00.0 - 2.450.24Out
 Put
DXCM250919P00050000153950.00.05 - 2.350.4Out
 Put
DXCM250919P0004500030345.00.0 - 2.252.25Out
 Put
DXCM250919P000400004440.00.0 - 0.80.05Out
 Put
DXCM250919P00035000235.00.0 - 2.150.1Out
 Put
DXCM250919P00030000330.00.0 - 0.30.15Out

DexCom Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

DexCom Total Stockholder Equity

Total Stockholder Equity

2.21 Billion

At this time, DexCom's Total Stockholder Equity is very stable compared to the past year.

DexCom Corporate Management

Shelly SelvarajSenior OfficerProfile
Leverne MarshExecutive MarketingProfile
Matthew DolanExecutive DevelopmentProfile
Teri LawverExecutive OfficerProfile
Donald AbbeyQuality ServicesProfile
Jereme SylvainCFO VPProfile
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.26)
Earnings Share
1.33
Revenue Per Share
10.533
Quarterly Revenue Growth
0.125
Return On Assets
0.0598
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.